In contrast to the TTP TMA group for which severe deficiency of ADAMTS-13 activity is confirmatory, our estimates of the non-TTP TMA incidence may be overestimated. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.